Financial Performance - For the fiscal year ending December 31, 2023, the company's revenue was RMB 397,998,000, a decrease of 1.8% compared to RMB 403,729,000 in 2022[11] - The gross profit for the same period was RMB 21,366,000, resulting in a gross margin of 5.37%, slightly down from 5.25% in 2024[11] - The company reported a loss attributable to shareholders of RMB 20,160,000, which is an improvement from a loss of RMB 27,452,000 in 2022[11] - Total assets as of December 31, 2023, were RMB 303,278,000, while total liabilities increased to RMB 238,699,000[11] - The total revenue for the year ended December 31, 2024, was RMB 385,482,322, a decrease of 3.14% compared to RMB 397,998,097 in 2023[43] - The comprehensive gross profit for the year was RMB 20,222,876, with a gross margin of 5.25%, down from 5.37% in the previous year[43] - The group reported a loss attributable to owners of RMB 27,802,241 for the year ended December 31, 2024, compared to a loss of RMB 20,159,658 for the year ended December 31, 2023, with a loss per share of RMB 1.46[50] Business Operations - The company operates in two main business areas: bio-composite fertilizers and elderly care services, with ongoing efforts in both sectors[7] - The company plans to expand its elderly care services and integrate management operations across the nation[7] - The gross profit margin for the bio-composite fertilizer segment has shown fluctuations, indicating potential areas for operational improvement[11] - The company established an e-commerce sales platform to expand market coverage and introduced new products such as liquid fertilizers and water-soluble compound fertilizers[17] - The company aims to enhance market marketing management and adjust product structure to improve market share in the compound fertilizer sector[23] - The company has expanded its product offerings to include liquid fertilizers and water-soluble compound fertilizers to meet market demand[34] Research and Development - The company is committed to enhancing its research and development capabilities in both fertilizer and healthcare sectors[7] - The company is actively developing new environmentally friendly fertilizer products in response to increasing quality demands from farmers[30] - The company is committed to integrating advanced technologies into its healthcare services to accelerate digital and intelligent upgrades in the elderly care sector[24] Market Trends - In 2024, the compound fertilizer market experienced structural adjustments, with nitrogen fertilizer prices fluctuating at low levels due to capacity release, while phosphate fertilizer remained high due to resource costs[16] - The national food production target is set to stabilize above 1.3 trillion jin, which is expected to drive rigid growth in fertilizer demand[17] - The fertilizer industry has improved its supply-demand balance and industry concentration due to structural reforms and stricter environmental policies[64] Corporate Governance - The company has appointed independent non-executive directors with extensive experience in accounting and law, enhancing governance and oversight[94][95][96] - The company is committed to ensuring compliance with its articles of association regarding board and supervisory board member requirements[87] - The board is led by Chairwoman Sun Li, who is responsible for the company's development strategy and risk management[126] - The company will seek to enhance corporate governance transparency and independence in the near future[129] Environmental Responsibility - The company maintains a corporate social responsibility strategy focused on employee care, environmental protection, and social responsibility[162] - The company adheres to strict environmental regulations, ensuring that emissions meet national standards[165] - Waste management practices include comprehensive utilization of solid waste, with all solid waste being recycled[165] - The company has implemented energy-saving measures and pollution control technologies in its operations[163] Financial Management - The audit committee held two meetings during the fiscal year and reviewed the financial reporting procedures of the group[117] - The financial statements for the year ending December 31, 2024, were audited by Fan Chen CPA Limited[121] - The company has provisions for shareholders to convene a special general meeting if they hold at least 10% of the issued share capital[157] - The total remuneration for executive director Sun Li for the fiscal year 2024 was RMB 516,303, a decrease of 16.7% from RMB 620,127 in 2023[153] Shareholder Engagement - The company emphasizes high transparency and timely disclosure of relevant information to shareholders[160] - The company encourages shareholder participation in annual general meetings, providing opportunities for direct dialogue[160]

Financial Performance - For the fiscal year ending December 31, 2024, the company reported a revenue of RMB 385,482,000, a decrease of 3.8% from RMB 397,998,000 in 2023[3] - The gross profit for 2024 was RMB 20,223,000, representing a gross margin of 5.25%, slightly down from 5.37% in 2023[3] - The net loss attributable to shareholders for 2024 was RMB 27,802,000, compared to a loss of RMB 20,160,000 in 2023, indicating a worsening financial performance[3] - The company reported a basic and diluted loss per share of RMB 1.46 for 2024, compared to RMB 1.06 in 2023, indicating a decline in shareholder value[6] - The company reported a total comprehensive loss of RMB 27,802,241 for the year ended December 31, 2024[12] - The company reported a loss attributable to owners of RMB (27,802,241) in 2024, compared to a loss of RMB (20,159,658) in 2023, indicating a significant increase in losses[40] - The group reported a loss attributable to owners of RMB 27,802,241 for the year ended December 31, 2024, compared to RMB 20,159,658 in 2023, with a loss per share of RMB 1.46, up from RMB 1.06[76] Assets and Liabilities - Total assets as of December 31, 2024, amounted to RMB 332,527,000, an increase from RMB 303,278,000 in 2023[3] - Total liabilities increased to RMB 304,087,000 in 2024 from RMB 238,699,000 in 2023, reflecting a significant rise in financial obligations[3] - The company’s non-current assets decreased to RMB 98,533,261 in 2024 from RMB 112,936,039 in 2023, reflecting a reduction in long-term investments[7] - Total equity attributable to shareholders dropped to RMB 22,149,067 in 2024 from RMB 49,951,308 in 2023, highlighting a significant decline in shareholder equity[8] - The group’s asset-liability ratio was 0.91 as of December 31, 2024, compared to 0.79 in 2023, indicating an increase in financial leverage[83] Cash Flow and Liquidity - The company’s cash and cash equivalents rose to RMB 25,399,950 in 2024, up from RMB 5,934,322 in 2023, indicating improved liquidity[7] - As of December 31, 2024, the company's current liabilities were approximately RMB 279,065,167, while cash and cash equivalents stood at only RMB 25,399,950, resulting in a net current liability position of RMB 45,071,379[53] - The company incurred total employee costs of RMB 27,726,792 in 2024, up from RMB 24,361,521 in 2023[36] Revenue Breakdown - Revenue from fertilizer products was RMB 384,846,908, down from RMB 397,424,063 in the previous year, indicating a decline of 3.1%[14] - The revenue from the sale of general fertilizers was RMB 359,752,928 in 2024, down from RMB 378,821,948 in 2023, representing a decline of about 5.0%[28] - Revenue from external customers for the year ended December 31, 2024, was RMB 385,482,322, a decrease from RMB 397,998,097 in 2023, representing a decline of approximately 3.8%[22][23] Research and Development - Research and development expenses for 2024 were RMB 1,102,139, a decrease from RMB 1,319,315 in 2023, suggesting a potential shift in focus or cost management[6] - Research and development expenses were RMB 1,102,139, a decrease of 16.46% from RMB 1,319,315 in the previous year, reflecting the R&D spending of the high-tech enterprise Guangdong Fuli Long[73] Strategic Moves - The company sold 82.76% of its stake in Shanghai Weidi Network Technology Co., Ltd., marking a strategic exit from the health products segment[18] - The company has classified Shanghai Weidi as a disposal group held for sale, terminating the operation of its "health products (alcohol) and related services" business[31] - The company plans to enhance product quality and develop new environmentally friendly fertilizers in response to increasing demands for fertilizer effectiveness and environmental regulations[59] Market and Industry Outlook - The composite fertilizer market experienced structural adjustments in 2024, with nitrogen fertilizer prices fluctuating at low levels and phosphate prices supported by resource costs[59] - The demand for composite fertilizers is expected to grow due to government policies aimed at stabilizing grain production above 1.3 trillion jin, enhancing farmers' planting enthusiasm[59] Shareholder Information - Major shareholders include state-owned assets management with 182,500,000 shares (9.63%), and Xiangyong Investment with 180,000,000 shares (9.50%) as of December 31, 2024[95] - The company has not declared or paid any dividends in both 2023 and 2024[39] Compliance and Governance - The company has complied with all provisions of the Corporate Governance Code except for A.2.1 during the review year, emphasizing effective board structure and transparency to shareholders[104] - The audit committee was established in accordance with GEM listing rules and consists of three independent non-executive directors, with a focus on financial reporting and internal controls[103]

k 天 津 泰 速 生 物 醫 學 工 程 股 份 有 限 公 司 Tianjin TEDA Biomedical Engineering Company Limited (於中華人民共和國註冊成立的股份有限公司) (股份代號：8189) 1 天津泰達生物醫學工程股份有限公司 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）的特色 GEM的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的中小型公司提供 一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周 詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等 內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有 關天津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公 ...

Financial Performance - For the six months ended June 30, 2024, the group achieved a consolidated revenue of RMB 211,568,049, representing a year-on-year growth of 16.24% compared to RMB 185,915,928 for the same period in 2023[3]. - The consolidated gross profit for the same period was RMB 12,115,570, reflecting a significant year-on-year increase of 76.90% from RMB 6,848,825 in 2023[3]. - The loss attributable to equity holders of the company was RMB 4,123,183, an improvement from a loss of RMB 11,250,040 in the previous year, with basic loss per share decreasing to RMB 0.218 from RMB 0.594[3][5]. - Revenue for the six months ended June 30, 2024, was RMB 211,568,049, an increase from RMB 185,915,928 in the same period of 2023, representing a growth of approximately 13.8%[10]. - Fertilizer product sales amounted to RMB 211,314,827 for the six months ended June 30, 2024, compared to RMB 181,559,688 in 2023, indicating a year-on-year increase of about 16.4%[10]. - The company reported a basic loss per share of RMB (4,123,183) for the six months ended June 30, 2024, compared to RMB (11,250,040) in the same period of 2023, showing an improvement in loss[14]. Assets and Liabilities - Non-current assets totaled RMB 109,650,049 as of June 30, 2024, down from RMB 112,936,039 as of December 31, 2023[6]. - Current assets increased to RMB 200,402,798 from RMB 190,341,927, with cash and bank balances rising significantly to RMB 18,199,595 from RMB 5,934,322[6][8]. - Current liabilities amounted to RMB 224,172,039, compared to RMB 216,842,145 at the end of 2023, resulting in a negative net current asset position of RMB 23,769,241[7]. - The total assets of the company were valued at RMB 310,052,847, an increase from RMB 303,277,966[7]. - Total liabilities, including other payables and accrued expenses, rose to RMB 51,997,572 as of June 30, 2024, compared to RMB 47,464,251 as of December 31, 2023[19]. - As of June 30, 2024, the company's total assets were approximately RMB 310,052,847, with total liabilities of RMB 224,172,039, resulting in a debt-to-asset ratio of 0.81[32]. Cash Flow and Financing - Cash flows from operating activities showed a net cash inflow of RMB 8,044,015, compared to RMB 1,915,186 in the previous year[8]. - The company raised RMB 15,000,000 through short-term/long-term bank borrowings during the period[8]. - Financing expenses increased to RMB 1,977,660 for the six months ended June 30, 2024, up from RMB 1,521,452 in the same period of 2023, reflecting a rise of approximately 30%[10]. - Financing costs rose by 29.99% to RMB 1,977,660, compared to RMB 1,521,452 in the same period last year[30]. Expenses - Sales and distribution costs increased by 33.65% to RMB 7,053,114, driven by higher marketing expenses and sales team commissions due to increased revenue scale[28]. - Research and administrative expenses decreased by 37.85% to RMB 8,559,614, down from RMB 13,773,232 in the previous year[29]. Corporate Governance - The board of directors did not recommend the payment of any dividend for the six months ended June 30, 2024[3]. - The company maintained a registered capital of RMB 189,450,000 as of June 30, 2024, consistent with the previous year[20]. - The effective corporate income tax rate remained at 25% for the group, with certain subsidiaries benefiting from reduced rates[11]. - The audit committee, consisting of three independent non-executive directors, has reviewed the interim results for the six months ending June 30, 2024[43]. - The board of directors believes that the company has complied with all provisions of the Corporate Governance Code except for the separation of roles between the chairman and the CEO[48]. - No interim dividend was declared for the six months ending June 30, 2024[49]. Market and Business Development - The company is actively developing elderly health resource allocation services and has expanded its rental services for assistive devices in multiple locations[26]. - The company has strengthened its market sales management and adjusted product structure in response to market demand, ensuring steady progress in its compound fertilizer business[25]. - The fertilizer industry is experiencing structural reforms, leading to improved supply-demand balance and increased industry concentration[36]. - The company plans to enhance marketing management and adjust product structure based on market demand to increase market share in the compound fertilizer sector[36]. - The company is focusing on the elderly care industry, providing management consulting services and collaborating with international institutions to enhance its professional capabilities[36]. - The company has developed auxiliary equipment rental and elderly food sales businesses, with plans to expand into more categories of elderly products[36]. Shareholder Information - Major shareholders include Tianjin Economic-Technological Development Area State-owned Assets Management Company with 9.63% and Xiangyong Investment with 9.50% of the shares[40]. - As of June 30, 2024, the company’s directors and supervisors do not have any competitive interests with the group’s business[42]. - No new share option plans were approved during the first half of 2024[44]. - The company has not entered into any management contracts for its overall or major business operations during the first half of 2024[45]. - The company did not repurchase any shares during the review period[47].

香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中 小型公司提供一個上市的市場。有意投資的人士應了解投資於該等公司的 潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關天津泰達生物醫學工程股份有限公司（「本公司」）的資料；本 公司董事願就本報告的資料共同及個別地承擔全部責任。本公司各董事在 作出一切合理查詢後，確認就其所知及所信，本報告所載資料在各重要方 面均屬準確完備，沒有誤導或欺詐成分，且並無遺漏任何事項，足以令致 本報告所載任何陳述或本報告產生誤導。 目錄 | 2 | 公司簡介 | | --- | --- | ...

Financial Performance - For the fiscal year ending December 31, 2023, the company reported a revenue of RMB 397,998,000, a decrease of 1.8% compared to RMB 403,729,000 in 2022[9] - The gross profit for 2023 was RMB 21,366,000, representing a gross margin of 5.37%, up from 3.67% in 2022[5] - The net loss attributable to shareholders for 2023 was RMB 20,160,000, an improvement from a loss of RMB 27,452,000 in 2022[5] - The company reported a basic and diluted loss per share of RMB 1.06 for 2023, compared to RMB 1.45 in 2022[9] - The company reported a total comprehensive loss of RMB 20,159,658 for the year ended December 31, 2023, compared to a loss of RMB 27,451,531 in 2022, indicating an improvement of about 26.5%[13] - The company reported a pre-tax loss of RMB 17,614,179 for the year 2023, compared to a loss of RMB 26,495,118 in 2022[32] - The company reported a loss before tax of RMB (5,601,754) in 2023, compared to a loss of RMB (2,439,963) in 2022, marking a 129.5% increase in losses[47] - The loss attributable to owners for the year was RMB 20,159,658, an improvement from RMB 27,451,531 in the previous year, with a loss per share of RMB 1.06 compared to RMB 1.45[99] Assets and Liabilities - Total assets decreased to RMB 303,278,000 in 2023 from RMB 337,196,000 in 2022[5] - Total liabilities were RMB 238,699,000 in 2023, down from RMB 256,046,000 in 2022[5] - Non-current liabilities decreased from RMB 37,797,202 in 2022 to RMB 21,856,336 in 2023, representing a reduction of approximately 42.2%[11] - Net assets decreased from RMB 81,149,764 in 2022 to RMB 64,579,485 in 2023, a decline of about 20.3%[11] - Total equity attributable to owners decreased from RMB 70,110,966 in 2022 to RMB 49,951,308 in 2023, reflecting a decrease of approximately 28.8%[13] - Total assets as of December 31, 2023, were RMB 303,277,966, down from RMB 337,196,239 in 2022, a decrease of 10.1%[37] - Total liabilities decreased to RMB 238,698,481 in 2023 from RMB 256,046,475 in 2022, a decline of 6.7%[37] Revenue Breakdown - Revenue from fertilizer products was RMB 397,424,063 in 2023, down from RMB 403,176,000 in 2022, reflecting a decline of 1.9%[25] - The segment for elderly care and health services generated revenue of RMB 574,034 in 2023, up from RMB 552,831 in 2022, an increase of 3.8%[25] - The revenue from the sale of general fertilizers in 2023 was RMB 378,821,948, slightly down from RMB 382,401,474 in 2022[41] - For the year ended December 31, 2023, the total revenue from the Chinese market was RMB 406,584,710, a decrease of 9.6% compared to RMB 449,675,951 in 2022[41] Cost Management and Expenses - The company continues to focus on cost management strategies to improve profitability in the upcoming fiscal year[9] - Research and development expenses for 2023 amounted to RMB 2,490,023, an increase from RMB 1,136,489 in 2022, reflecting a significant investment in innovation[39] - Sales and distribution costs decreased by 22.96% to RMB 8,101,974, down from RMB 10,516,917 in the previous year, primarily due to changes in the sales structure of compound fertilizer products[93] - Administrative expenses decreased by 3.93% to RMB 21,803,601 from RMB 22,695,980 in the previous year, attributed to cost-saving measures[95] - Financing costs decreased by 19.19% to RMB 5,172,914 from RMB 6,401,355 in the previous year, due to lower bank loan interest rates[97] Inventory and Receivables - Inventory increased to RMB 90,456,000 in 2023 from RMB 74,004,000 in 2022, indicating a rise in stock levels[10] - Trade receivables decreased significantly to RMB 8,776,000 in 2023 from RMB 31,866,000 in 2022, reflecting improved collection efforts[10] - Accounts receivable decreased significantly to RMB 8,776,649 in 2023 from RMB 31,866,638 in 2022[25] - Total accounts receivable as of December 31, 2023, amounted to RMB 102,165,062, compared to RMB 126,318,040 in 2022, indicating a reduction in receivables[71] Strategic Initiatives - The company has plans for market expansion and new product development, although specific details were not disclosed in the earnings call[9] - The company plans to continue focusing on the delivery of biological compound fertilizers, with expected revenue recognition from contract liabilities in the next 12 months[26] - The company is actively considering fundraising activities, including rights issues and public offerings, to raise new capital[87] - The company has been developing elderly health resource allocation services, including the rental of assistive devices and the sale of elderly health products[90] - The company aims to expand its elderly health product offerings, including rental of assistive devices and sales of elderly food products, to create a new profit growth point[119] Market Conditions - The fertilizer business faced significant price declines in coal, nitrogen, phosphorus, and potassium products in the first half of 2023, leading to cautious inventory management by downstream distributors[88] - The company has strengthened market sales management and adjusted product structures in response to market demand, ensuring stable progress in the compound fertilizer business[88] Governance and Compliance - The company has not applied new accounting standards that have been issued but are not yet effective, indicating a cautious approach to upcoming regulatory changes[23] - The company has not entered into any management contracts for overall business or any major business operations during the year[127] - The audit committee held five meetings during the fiscal year to review the company's audited annual results[135] - The company has complied with all provisions of the Corporate Governance Code, except for one specific provision during the review year[137] Future Outlook - The company reported a significant increase in revenue, with a year-over-year growth of 25% in Q1 2024[140] - The company projects a revenue guidance of $200 million for Q2 2024, reflecting a 20% growth from Q1 2024[140] - New product launches are expected to contribute an additional $50 million in revenue by the end of 2024[140] - Market expansion plans include entering two new international markets by Q3 2024, targeting a 10% increase in overall market share[140]

Financial Performance - For the nine months ended September 30, 2023, the group achieved a total revenue of RMB 305,231,488, representing a year-on-year increase of 0.08% compared to RMB 304,972,430 for the same period in 2022[3] - The gross profit for the nine months ended September 30, 2023, was RMB 11,500,176, reflecting a year-on-year growth of 2.79% from RMB 11,188,179 in 2022[3] - The loss attributable to equity holders for the nine months ended September 30, 2023, was RMB 17,294,189, an improvement from a loss of RMB 21,627,090 in the same period of 2022[4] - The basic loss per share for the nine months ended September 30, 2023, was RMB 0.913, compared to a loss of RMB 1.142 per share for the same period in 2022[4] - The group reported a pre-tax loss of RMB 20,003,700 for the nine months ended September 30, 2023, compared to a pre-tax loss of RMB 21,852,487 in 2022[10] Revenue Breakdown - Revenue from fertilizer products for the nine months ended September 30, 2023, was RMB 296,564,295, down from RMB 303,458,927 in 2022[6] - Revenue from elderly care and health services for the nine months ended September 30, 2023, increased to RMB 8,667,193 from RMB 1,513,503 in 2022[6] - For the nine months ended September 30, 2023, the company reported a total operating revenue of RMB 305,231,488, a year-on-year increase of 0.08% compared to RMB 304,972,430 for the same period in 2022[15] Cost Management - Sales and distribution costs decreased by 25.74% to RMB 6,956,908 from RMB 9,368,063 in the previous year[15] - Research and administrative expenses were reduced by 4.17% to RMB 21,541,186 compared to RMB 22,477,429 in the previous year[15] - The group incurred financing costs of RMB 2,538,214 for the nine months ended September 30, 2023, down from RMB 4,100,365 in 2022[4] - Financing costs decreased significantly by 38.10% to RMB 2,538,214 from RMB 4,100,365 in the previous year[15] Dividend and Shareholder Information - The group did not recommend the payment of dividends for the nine months ended September 30, 2023[4] - The company does not recommend the payment of an interim dividend for the nine months ended September 30, 2023[12] - As of September 30, 2023, the company has 300,000,000 shares held by both Ms. Sun Li and Mr. He Xin, representing 15.83% of the issued share capital each[22] - Major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., Ltd. with 182,500,000 shares (9.63%), Shenzhen Xiangyong Investment Co., Ltd. with 180,000,000 shares (9.50%), and Guangdong Jiamei Ecological Technology Co., Ltd. with 180,000,000 shares (9.50%) as of September 30, 2023[26] Corporate Governance - The company has complied with all provisions of the Corporate Governance Code, except for the separation of the roles of Chairman and CEO as required by the code[33] - The company has not approved any new share option schemes during the period ending September 30, 2023[30] - No shares were repurchased, purchased, or sold by the company or its subsidiaries during the review period[32] Strategic Plans - The company plans to enhance market management and adjust product structure to improve market share in the compound fertilizer industry[20]

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二三年第三季度業績公告 GEM GEM 香港聯合交易所有限公司（「聯交所」） （「 」）的特色 GEM 的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公告的資料乃遵照聯交所 證券上市規則（「 上市規則」）而刊載，旨在提供有關天津 泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本公 ...

Financial Performance - For the six months ended June 30, 2023, the group achieved a total revenue of RMB 185,915,928, a decrease of 9.40% compared to RMB 205,210,475 for the same period in 2022[4] - The gross profit for the same period was RMB 6,848,825, representing a decline of 33.96% from RMB 10,370,957 in the previous year[4] - The loss attributable to equity holders of the company was RMB 11,250,040, an improvement from a loss of RMB 13,248,062 in the prior year[4] - The basic loss per share for the period was RMB 0.594, compared to RMB 0.699 for the same period last year[4] - The company's comprehensive gross profit for the same period was RMB 6,848,825, a year-on-year decrease of 33.96% from RMB 10,370,957 in 2022, resulting in a gross profit margin of 3.68% compared to 5.05% in the previous year[32] Assets and Liabilities - The total assets as of June 30, 2023, amounted to RMB 326,577,334, down from RMB 337,196,239 at the end of 2022[6] - Current liabilities totaled RMB 221,585,923, compared to RMB 218,249,273 at the end of 2022, indicating a slight increase[7] - The net asset value of the company was RMB 69,757,798, a decrease from RMB 83,713,353 at the end of the previous year[7] - The net receivables from trade accounts as of June 30, 2023, were RMB 20,359,441, down from RMB 31,866,638 as of December 31, 2022, reflecting a decrease of 36.1%[19] - The company's prepayments and other receivables totaled RMB 61,312,181 as of June 30, 2023, down from RMB 77,654,553 as of December 31, 2022, a decrease of 21.1%[20] - The group's debt-to-asset ratio was 0.79 as of June 30, 2023, compared to 0.75 as of December 31, 2022[38] Cash Flow and Investments - Operating cash flow for the six months ended June 30, 2023, was RMB 3,102,287, compared to a cash outflow of RMB 18,428,270 in the same period of 2022[6] - The net cash used in investing activities for the six months ended June 30, 2023, was RMB 1,288,270, compared to RMB 3,198,037 in the same period of 2022, indicating a decrease of 59.7%[6] - The company invested approximately RMB 461,949 in property, plant, and equipment during the period, significantly lower than RMB 1,428,453 in the same period of 2022[17] Expenses - Research and development expenses for the period were RMB 13,773,232, compared to RMB 12,242,150 in the previous year, indicating increased investment in R&D[5] - The company's income tax expense for the six months ended June 30, 2023, was RMB -41,394, compared to RMB 146,275 in the same period of 2022, indicating a reduction in tax liability[14] - The group's sales and distribution costs for the six months ended June 30, 2023, were RMB 5,277,328, a decrease of 35.00% compared to RMB 8,118,740 for the same period in 2022[33] - Research and administrative expenses increased by 12.51% to RMB 13,773,232 for the six months ended June 30, 2023, compared to RMB 12,242,150 in the same period of 2022[34] - Financing costs decreased by 54.32% to RMB 1,521,452 for the six months ended June 30, 2023, down from RMB 3,330,598 in the same period of 2022[35] Dividends - The company did not recommend the payment of any dividend for the six months ended June 30, 2023[4] - The company has not proposed an interim dividend for the six months ended June 30, 2023, consistent with no dividend declared for the same period in 2022[26] - The company did not declare any interim dividend for the six months ending June 30, 2023[58] Business Operations - The company is involved in two main business areas: bio-composite fertilizers and elderly care services, focusing on the integration of medical and elderly care services[28] - The company has strengthened its market sales management and adjusted product structure in response to market conditions, aiming to stabilize its bio-composite fertilizer business[29] - The company has expanded its elderly health resource allocation business, including the rental of assistive devices and the sale of elderly food products[31] - The aging population in China, with 280 million people aged 60 and above, presents significant opportunities for the elderly care services sector, which the group aims to develop further[43] - The group has developed elderly health resource allocation services, including assistive device rentals and elderly food sales, with plans to expand into more categories[43] Governance and Management - The audit committee reviewed the interim results and report for the six months ending June 30, 2023[52] - No new share option schemes were approved during the first half of 2023[53] - The company did not purchase, sell, or redeem any of its shares during the review period[56] - The company has not entered into any management contracts for its overall business or any major business during the first half of 2023[54] - The board of directors and management are committed to implementing the corporate governance code as per GEM listing rules[57] - There were no reported conflicts of interest or competition with the company's business as of June 30, 2023[50] - The company is currently led by co-CEOs Sun Li and Qin Wenhua, with Sun also serving as the chairperson[57] - The company maintains a focus on transparency and effective internal controls in its governance practices[57] Shareholder Information - As of June 30, 2023, major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., Ltd. with 182,500,000 shares (9.63%), Xiangyong Investment with 180,000,000 shares (9.50%), and Guangdong Jiamei Ecological Technology Co., Ltd. with 180,000,000 shares (9.50%)[48]

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二三年半年度業績公告 GEM GEM 香港聯合交易所有限公司（「聯交所」） （「 」）的特色 GEM 的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公告的資料乃遵照聯交所《 證券上市規則》（「 上市規則」）而刊載，旨在提供有關天 津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司的董事願就 ...